Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2683]

First genetically engineered cancer model in naked mole rats developed

First genetically engineered cancer model in naked mole rats developed

WCLC 2025: First-ever clinical trial demonstrates safety, molecular readout and promise of pre- and post-surgery immunotherapy combination for patients with operable mesothelioma

WCLC 2025: First-ever clinical trial demonstrates safety, molecular readout and promise of pre- and post-surgery...

GLP-1 receptor agonists improve lung cancer outcomes

GLP-1 receptor agonists improve lung cancer outcomes

WCLC 2025: Video assisted thoracoscopy surgery reduces mortality by 21 percent compared to lobectomy

WCLC 2025: Video assisted thoracoscopy surgery reduces mortality by 21 percent compared to lobectomy

WCLC 2025: Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds

WCLC 2025: Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds

WCLC 2025: Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

WCLC 2025: Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell...

$WCLC 2025: Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and lower toxicity to conventional schedule in LS-SCLC$

WCLC 2025: Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and...

WCLC 2025: Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

WCLC 2025: Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant...

WCLC 2025: First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed SCLC

WCLC 2025: First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in...

WCLC 2025: FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

WCLC 2025: FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced...

More from ecancer